{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:56:15Z","timestamp":1792461375349,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.antiviral.2020.104815","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T20:31:07Z","timestamp":1588624267000},"page":"104815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["HBV replication inhibitors"],"prefix":"10.1016","volume":"179","author":[{"given":"Claire","family":"Pierra Rouviere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-5032","authenticated-orcid":false,"given":"Cyril B.","family":"Dousson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Tavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104815_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib2","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.cgh.2018.11.001","article-title":"Efficacy and safety of besifovir dipivoxyl maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection","volume":"17","author":"Ahn","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib3","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jhep.2016.02.012","article-title":"Experimental in vitro and in vivo models for the study of human hepatitis B virus infection","volume":"64","author":"Allweiss","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.29509","article-title":"A research agenda for curing chronic hepatitis B virus infection","volume":"67","author":"Alter","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104815_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1358\/dot.2009.45.5.1354223","article-title":"Clevudine for hepatitis B","volume":"45","author":"Anderson","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.antiviral.2020.104815_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hiv.12401","article-title":"The role of tenofovir alafenamide in future HIV management","volume":"17","author":"Antela","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2020.104815_bib7","first-page":"37","article-title":"Agenix, IMB to develop Hep B drug in China","volume":"14","year":"2010","journal-title":"Asia Pac. Biotech. News"},{"key":"10.1016\/j.antiviral.2020.104815_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","author":"Babusis","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2020.104815_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP2770","article-title":"Tenofovir alafenamide is not a substrate for renal organion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity","volume":"19","author":"Bam","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104815_bib10","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1136\/gutjnl-2015-309300","article-title":"Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B","volume":"66","author":"Bayliss","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2020.104815_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818786108","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence","volume":"11","author":"Byrne","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2014.05.007","article-title":"Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity","volume":"108","author":"Cai","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib14","doi-asserted-by":"crossref","first-page":"15125","DOI":"10.1021\/acsomega.8b01754","article-title":"Synthesis and evaluation of troponoids as a new class of antibiotics","volume":"3","author":"Cao","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.antiviral.2020.104815_bib15","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2174\/0929867321666140120121158","article-title":"Recent progress in the research of small molecule HIV-1 RNase H inhibitors","volume":"21","author":"Cao","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104815_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2020.104815_bib18","first-page":"S147","article-title":"Pharmacokinetics, safety and tolerability of CMX157, a novelprodrug of tenofovir, administered as ascending multiple dosesto healthy volunteers and HBV-infected subjects","volume":"11","author":"Chatsiricharoenkul","year":"2017","journal-title":"Hepatol. Int"},{"key":"10.1016\/j.antiviral.2020.104815_bib19","first-page":"65","article-title":"Regulation mechanism of HBV cccDNA","volume":"1","author":"Cheng","year":"2012","journal-title":"Infect. Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib20","article-title":"Phase 3 study of besifovir","year":"2013","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.antiviral.2020.104815_bib21","article-title":"A phase 1 double-blinded study for safety, tolerability, pharmacokinetics, and antiviral activity of ATI-2173 in healthy subjects and subjects with chronic hepatitis B virus infection","year":"2020","journal-title":"Clin. Trials.gov"},{"key":"10.1016\/j.antiviral.2020.104815_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2893.2010.01321.x","article-title":"Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy","volume":"18","author":"Coffin","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2020.104815_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1707186","article-title":"Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase","volume":"252","author":"Davies","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104815_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00535-020-01680-0","article-title":"Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review","volume":"55","author":"de Fraga","year":"2020","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib25","series-title":"International Patent WO2017223421 A1","author":"De La Rosa","year":"2017"},{"key":"10.1016\/j.antiviral.2020.104815_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12072-017-9797-y","article-title":"Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects","volume":"11","author":"Ding","year":"2017","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02574-16","article-title":"Troponoids can inhibit growth of the human fungal pathogen Cryptococcus neoformans","volume":"61","author":"Donlin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"EASL","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.04.012","article-title":"Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles","volume":"143","author":"Edwards","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2019.02.005","article-title":"Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors","volume":"164","author":"Edwards","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib31","first-page":"1574","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis","volume":"132","author":"Ghany","year":"2007","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.antiviral.2020.104815_bib33","unstructured":"Honghai, L., 2019. Tenofovir Diester Compounds and Salts Thereof, Preparation Method and Medicine Application of Compounds, China patent CN109400647 A."},{"key":"10.1016\/j.antiviral.2020.104815_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","article-title":"beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"99","author":"Hu","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib35","article-title":"3-Hydroxypyrimidine-2,4-Diones as novel hepatitis B virus antivirals targeting the viral ribonuclease","volume":"61","author":"Huber","year":"2017","journal-title":"H. Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/biology1030521","article-title":"Inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H activity","volume":"1","author":"Ilina","year":"2012","journal-title":"Biology"},{"key":"10.1016\/j.antiviral.2020.104815_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-020-10024-2","article-title":"Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis","author":"Jia","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib38","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/AAC.00599-13","article-title":"Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine","volume":"57","author":"Jones","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib39","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.3390\/molecules15095878","article-title":"Discovery and development of anti-HBV agents and their resistance","volume":"15","author":"Kim","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2020.104815_bib40","first-page":"439","article-title":"Advances in hepatology: emerging therapies toward a functional cure for hepatitis B virus infection","volume":"14","author":"Kim","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib41","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1093\/nar\/gkg881","article-title":"Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors","volume":"31","author":"Klumpp","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib42","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2020.104815_bib44","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/gutjnl-2013-305138","article-title":"Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B","volume":"63","author":"Lai","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2020.104815_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3851\/IMP1510","article-title":"Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B","volume":"15","author":"Lee","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104815_bib47","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/S0168-8278(06)80742-7","article-title":"741 Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study","volume":"44","author":"Lee","year":"2006","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2020.104815_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/liv.12057","article-title":"Impact of therapy on the outcome of chronic hepatitis B","volume":"33","author":"Liaw","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib49","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","article-title":"Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift","volume":"13","author":"Liaw","year":"2019","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib50","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1128\/AAC.01566-05","article-title":"Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer","volume":"50","author":"Lin","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib51","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/JVI.02147-07","article-title":"Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104815_bib52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2020.104815_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104815_bib54","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104815_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02441-16","article-title":"Synergistic interactions between hepatitis B virus RNase H antagonists and other inhibitors","volume":"61","author":"Lomonosova","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.antiviral.2017.11.008","article-title":"Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice","volume":"149","author":"Long","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib57","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.04617-14","article-title":"Hydroxylated tropolones inhibit hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"59","author":"Lu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2016.09.009","article-title":"Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors","volume":"135","author":"Lu","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib59","doi-asserted-by":"crossref","first-page":"12558","DOI":"10.3748\/wjg.v21.i44.12558","article-title":"Hepatitis B virus therapy: what's the future holding us","volume":"21","author":"Manzoor","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib60","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104815_bib61","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104815_bib62","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.biocel.2012.04.006","article-title":"Antiviral therapies: focus on hepatitis B reverse transcriptase","volume":"44","author":"Michailidis","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.antiviral.2020.104815_bib63","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1128\/AAC.00263-09","article-title":"Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis","volume":"53","author":"Michalak","year":"2009","journal-title":"B. Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib64","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ajg.2009.726","article-title":"Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop","volume":"105","author":"Monto","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib65","first-page":"177","article-title":"Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function","volume":"60","author":"Murakami","year":"2014","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"10.1016\/j.antiviral.2020.104815_bib66","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00535-019-01643-0","article-title":"Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay","volume":"55","author":"Nakajima","year":"2019","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135965350801300206","article-title":"Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes","volume":"13","author":"Niu","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104815_bib69","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104815_bib70","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.00460-07","article-title":"Evaluation of hexadecyloxypropyl-9-R-[2-phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections","volume":"51","author":"Painter","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib71","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/liv.13059","article-title":"Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study","volume":"36","author":"Park","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib72","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3346\/jkms.2017.32.11.1857","article-title":"Clevudine induced mitochondrial pyopathy","volume":"32","author":"Park","year":"2017","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.antiviral.2020.104815_bib73","first-page":"348","article-title":"New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection","volume":"13","author":"Peters","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib75","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/jm7012216","article-title":"Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B","volume":"51","author":"Reddy","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104815_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrgastro.2016.7","article-title":"Global strategies are required to cure and eliminate HBV infection","volume":"13","author":"Revill","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib78","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4254\/wjh.v6.i6.384","article-title":"Clinical impact of occult hepatitis B virus infection in immunosuppressed patients","volume":"6","author":"Sagnelli","year":"2014","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib79","series-title":"Fields Virology","first-page":"2185","article-title":"Hepadnaviruses","author":"Seeger","year":"2013"},{"key":"10.1016\/j.antiviral.2020.104815_bib80","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/med.21490","article-title":"2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: a novel anti-HBV agent, active against drug-resistant HBV mutants","volume":"38","author":"Singh","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.antiviral.2020.104815_bib81","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/acs.joc.8b02599","article-title":"Synthesis of an anti-hepatitis B agent, 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA) and its phosphoramidate (FMCAP)","volume":"84","author":"Singh","year":"2019","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2020.104815_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206618775243","article-title":"Phosphoramidates and phosphonamidates (ProTides) with antiviral activity","volume":"26","author":"Slusarczyk","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2020.104815_bib84","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1440-1746.2011.06766.x","article-title":"Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir","volume":"26","author":"Takkenberg","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003125","article-title":"The hepatitis B virus ribonuclease h is sensitive to inhibitors of the human immunodeficiency virus ribonuclease h and integrase enzymes","volume":"9","author":"Tavis","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104815_bib86","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/jvi.68.6.3536-3543.1994","article-title":"Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer","volume":"68","author":"Tavis","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104815_bib87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104815_bib88","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12072-016-9745-2","article-title":"Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia","volume":"10","author":"Tian","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib89","first-page":"682","article-title":"Pradefovir, a liver-targeted prodrug of adefovir against HBV infection","volume":"8","author":"Tillmann","year":"2007","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2020.104815_bib90","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104815_bib91","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2016.06.005","article-title":"Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors","volume":"132","author":"Villa","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib92","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/acsmedchemlett.9b00184","article-title":"Design, synthesis, and anti-HBV activity of new bis(l-amino acid) ester tenofovir prodrugs","volume":"10","author":"Wang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2020.104815_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2014.01.009","article-title":"Efficacy of 2 years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment","volume":"103","author":"Wang","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib94","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.3748\/wjg.v20.i24.7707","article-title":"Emerging antivirals for the treatment of hepatitis B","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2020.104815_bib95","unstructured":"Wang, Y., Zhao, J., 2019a. Antiviral nuleoside reverse transcriptase inhibitor, International Patent WO2019120084 A1."},{"key":"10.1016\/j.antiviral.2020.104815_bib96","unstructured":"Wang, Y., Zhao, J., 2019b. Novel antiviral nucleoside reverse transcriptase inhibitor, International Patent WO2019120071 A1."},{"key":"10.1016\/j.antiviral.2020.104815_bib97","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1128\/AAC.01764-09","article-title":"Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104815_bib98","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently cosed circuar DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib99","series-title":"About Viral Hepatitis","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.antiviral.2020.104815_bib100","unstructured":"Xinglu, Z., Xingguo, L., Miao, H., Xiaowu, D., Wenhai, H., 2019. Phosphoramidate Prodrug of Nucleoside Analogues, a Pharmaceutical Composition and Applications of the Phosphoramidate Prodrug, China Patent CN109535200 A."},{"key":"10.1016\/j.antiviral.2020.104815_bib101","unstructured":"Yi, S., Chen, D., Liu, H., Wang, Y., Jia, J., Luo, J., Hui, S., 2017a. Alkylalkoxy Ester Produg of Nuleoside Analogue and Use Thereof, China patent WO2017124895."},{"key":"10.1016\/j.antiviral.2020.104815_bib102","unstructured":"Yi, S., He, Y., Xiao, N., Pan, X., Luo, J., Hui, S., 2017b. Phosphate Prodrug of Nucleoside Analogue and Use Thereof, China Patent WO2017124896."},{"key":"10.1016\/j.antiviral.2020.104815_bib103","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cgh.2019.08.033","article-title":"How do we determine whether a functional cure for HBV infection has been achieved","volume":"18","author":"Yip","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib104","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2014.10.026","article-title":"Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study","volume":"62","author":"Yuen","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104815_bib105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.23462","article-title":"Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease","volume":"51","author":"Yuen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104815_bib106","doi-asserted-by":"crossref","first-page":"104693","DOI":"10.1016\/j.antiviral.2019.104693","article-title":"Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection","volume":"174","author":"Zhang","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib107","unstructured":"Zhijian, X., Huaqiang, X., Chunping, L., Zhongshan, W., 2019a. Liver specific delivery-based entecavir prodrug, nucleoside cyclic phosphate compound, and application thereof, International Patent WO2019120301 A1."},{"key":"10.1016\/j.antiviral.2020.104815_bib108","unstructured":"Zhijian, X., Huaqiang, X., Chunping, L., Zhongshan, W., Feng, S., Zhenwei, Z., 2019b. Liver Specific Delivery-Based Antiviral Prodrug Nucleoside Cyclophosphate Compound and Uses Thereof, USA Patent US2019125771 A1."},{"key":"10.1016\/j.antiviral.2020.104815_bib109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2012.02.030","article-title":"In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates","volume":"683","author":"Zhou","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104815_bib110","unstructured":"Zhuorong, L., Zongying, L., Hong, Y., Yanping, L., 2012. Preparation Method of Acyclic Nucleoside Antiviral Drug Phosphoric Acid Monoester Compound. China Patent CN102417521."},{"key":"10.1016\/j.antiviral.2020.104815_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.07.003","article-title":"Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection","volume":"64","author":"Zoulim","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104815_bib112","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12072-016-9737-2","article-title":"Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure","volume":"10","author":"Zoulim","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104815_bib113","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:53Z","timestamp":1759062713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":113,"alternative-id":["S0166354220302291"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104815","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBV replication inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104815"}}